Prescribing information

 

Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis in adults who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation (CRP and/or MRI evidence) in adults who have responded inadequately to non-steroidal anti-inflammatory drugs.

Help newly initiated Cosentyx patients keep track of their treatment with a digital dosing schedule. As a healthcare professional, you should download the document and fill in the patient’s planned injection dates, as shown in the example below.

Share the completed file with your patients and they can simply tick the circles after they administer their Cosentyx dose, as shown in the example below:

Please note that this resource is designed for optimal use on desktop or tablet. Functionality may be restricted on some devices including mobile.

Download the dosing schedule for the relevant indication below.

Do not share links to this website or screenshots with patients as this website is intended for healthcare professionals only.

 

Download PsA dosing schedule  

Download axSpA (AS & nr-axSpA) dosing schedule

 

For more information on Cosentyx dosing, please see dosing and product information.

AS, ankylosing spondylitis; CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drug; MRI, magnetic resonance imaging; MTX, methotrexate; nr-axSpA, non-radiographic axial spondyloarthritis; PsA, psoriatic arthritis.

Rate this content: 
No votes yet
UK | May 2021 | 108790
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]